Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma

NEXT STORY
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern
PREV STORY
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection

author_avatar
NASDAQ Market News

Global Rare Disease Diagnostics Market: Focus on Disease, Trait Type, Products, Age Group, Test Type, Technology, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030

author_avatar
NASDAQ Market News

PreCheck Health Services, Inc. appoints Dr. Mitch Ghen as its Chief Science Officer

author_avatar
NASDAQ Market News